Clear Search sequence regions


  • antigens (4)
  • cancer (3)
  • cyclotron (1)
  • half life (1)
  • human cells (1)
  • humans (1)
  • mice (2)
  • mice nod (1)
  • mice scid (1)
  • prostate (5)
  • PSMA1 (6)
  • PSMA5 (9)
  • PSMA6 (3)
  • radiopharmaceuticals (2)
  • SCID (1)
  • treatment effect (4)
  • tumor size (1)
  • xenograft (3)
  • Sizes of these terms reflect their relevance to your search.

    Targeted α-therapy (TAT) for prostate-specific membrane antigen (PSMA) is a promising treatment for metastatic castration-resistant prostate cancer (CRPC). Astatine is an α-emitter (half-life=7.2 h) that can be produced by a 30-MeV cyclotron. This study evaluated the treatment effect of 211At-labeled PSMA compounds in mouse xenograft models. Tumor xenograft models were established by subcutaneous transplantation of human prostate cancer cells (LNCaP) in NOD/SCID mouse. [211At]PSMA1, [211At]PSMA5, or [211At]PSMA6 was administered to LNCaP xenograft mice to evaluate biodistribution at 3 and 24 h. The treatment effect was evaluated by administering [211At]PSMA1 (0.40 ± 0.07 MBq), [211At]PSMA5 (0.39 ± 0.03 MBq), or saline. Histopathological evaluation was performed for the at-risk organs at 3 and 6 weeks after administration. [211At]PSMA5 resulted in higher tumor retention compared to [211At]PSMA1 and [211At]PSMA6 (30.6 ± 17.8, 12.4 ± 4.8, and 19.1 ± 4.5 %ID/g at 3 h versus 40.7 ± 2.6, 8.7 ± 3.5, and 18.1 ± 2.2%ID/g at 24 h, respectively), whereas kidney excretion was superior in [211At]PSMA1 compared to [211At]PSMA5 and [211At]PSMA6. An excellent treatment effect on tumor growth was observed after [211At]PSMA5 administration. [211At]PSMA1 also showed a substantial treatment effect; however, the tumor size was relatively larger compared to that with [211At]PSMA5. In the histopathological evaluation, regenerated tubules were detected in the kidneys at 3 and 6 weeks after the administration of [211At]PSMA5. TAT using [211At]PSMA5 resulted in excellent tumor growth suppression with minimal side effects in the normal organs. [211At]PSMA5 should be considered a new possible TAT for metastatic CRPC, and translational prospective trials are warranted. © 2022. The Author(s).

    Citation

    Tadashi Watabe, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Yuichiro Kadonaga, Kazuhiro Ooe, Yang Wang, Hiromitsu Haba, Atsushi Toyoshima, Jens Cardinale, Frederik L Giesel, Noriyuki Tomiyama, Koichi Fukase. Targeted α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound. European journal of nuclear medicine and molecular imaging. 2023 Feb;50(3):849-858

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 36344651

    View Full Text